http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2664248-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78cecb870dabca115530db05dd0af06f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2800-75 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-0295 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-342 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-63 |
| filingDate | 2007-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_433f42d6fb79f8311e003884502fab94 |
| publicationDate | 2018-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2664248-T3 |
| titleOfInvention | Composition for topical application |
| abstract | Composition for topical application for application in infants or young children, which has a hydrophilic liquid, at least one anti-inflammatory active principle as well as at least one support substance for the active principle, in which the support substance with The hydrophilic liquid forms lamellar structures, characterized a) because the lamellar structures are double lamellar membrane structures with a layered structure, in which a first layer of support substance is oriented in parallel and planar to a second layer of substance of support and the hydrophilic remains of each layer of support substance are positioned outwardly and the lipophilic remains of each layer of support substance are positioned inwardly, b) because between the hydrophilic residues arranged as a layer in the area of the remains lipophilic is distributed the anti-inflammatory active substance homogeneously mono- or oligodispersed, c) p orque the composition has as a support substance a hydrogenated phospholipid with a phase transition temperature above 30 ° C and below 70 ° C and d) because the composition presents as active ingredient an anti-inflammatory active ingredient that is selected from the group that It comprises ursolic acid, soy sterol, 18-beta-glycyrrhetic acid, gamma-oryzanol, ferulic acid. |
| priorityDate | 2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.